Reduction in serum total cholesterol and risks of coronary events and cerebral infarction in Japanese men: the Kyushu Lipid Intervention Study.

Lowering serum total cholesterol is shown to decrease the risk of coronary heart disease (CHD) in Western countries,but evidence is limited regarding cerebral infarction (CI). The present study used the Kyushu Lipid Intervention Study to examine the risks of CHD events and CI in relation to reduction in serum total cholesterol. Subjects were 4,615 men aged 45-74 years with serum total cholesterol of 220 mg/dl (5.68 mmol/L) or greater who had no history of CHD events or stroke. CHD events and CI numbered 125 and 92, respectively, in a 5-year follow-up. After adjustment for potential confounding factors, the relative risks of CHD events and CI for 15% or greater reduction in total cholesterol, compared with less than 5% reduction, were 0.78 (95% confidence limit [CL]0.46-1.32) and 0.39 (95% CL 0.22-0.69), respectively. As compared with on-treatment cholesterol levels of 240 mg/dl (6.20 mmol/L)or higher, the risk of CHD events was approximately 50% lower across 3 categories below 240 mg/dl (6.20 mmol/L), and that of CI was 70%lower at 2 categories below 220 mg/dl (5.68 mmol/L). Lowering serum total cholesterol below 220 mg/dl (5.68 mmol/L) seems desirable with regard to the prevention of CI.

[1]  Y. Matsuzawa,et al.  Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[2]  Y. Liu,et al.  Medication for hypercholesterolemia and the risk of nonfatal acute myocardial infarction: case-control study in Japan. , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[3]  A. Takeshita,et al.  Role of hypertension, dyslipidemia and diabetes mellitus in the development of coronary atherosclerosis in Japan. , 2001, Japanese circulation journal.

[4]  B. Davis,et al.  Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project , 2001, Circulation.

[5]  S. Yamashita,et al.  Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees: a case-control study. , 2001, Japanese circulation journal.

[6]  Y. Miyake Risk Factors for Non-Fatal Acute Myocardial Infarction in Middle-Aged and Older Japanese , 2000 .

[7]  Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study. , 2000, Journal of atherosclerosis and thrombosis.

[8]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[9]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[10]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[11]  Alan C. Wilson,et al.  Risk factors for stroke and type of stroke in persons with isolated systolic hypertension , 1998 .

[12]  Y. Friedlander,et al.  Risk factors for ischemic stroke: Dubbo Study of the elderly. , 1998, Stroke.

[13]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[14]  B. Davis,et al.  Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. , 1998, Stroke.

[15]  C. Hennekens,et al.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.

[16]  R. Westendorp,et al.  Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. , 1997, Stroke.

[17]  N. Yoshiike,et al.  A 15.5-year follow-up study of stroke in a Japanese provincial city. The Shibata Study. , 1997, Stroke.

[18]  D. Tanné,et al.  High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. , 1997, Stroke.

[19]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[20]  A coronary primary intervention study of Japanese men: study design, implementation and baseline data. The Kyushu Lipid Intervention Study Group. , 1996, Journal of atherosclerosis and thrombosis.

[21]  D. Kromhout Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts , 1995, The Lancet.

[22]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[23]  C. Furberg,et al.  Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. , 1995, Circulation.

[24]  C. Hennekens,et al.  An overview of trials of cholesterol lowering and risk of stroke. , 1995, Archives of internal medicine.

[25]  Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[26]  H. Mabuchi,et al.  Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. , 1994, The Journal of clinical investigation.

[27]  G. Boysen,et al.  Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen city heart study , 1994, BMJ.

[28]  Katsuhiko Yano,et al.  Elevated Serum Cholesterol Is a Risk Factor for Both Coronary Heart Disease and Thromboembolic Stroke in Hawaiian Japanese Men: Implications of Shared Risk , 1994, Stroke.

[29]  David C. Atkins,et al.  Cholesterol Reduction and the Risk for Stroke in Men , 1993, Annals of Internal Medicine.

[30]  R Peto,et al.  Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. , 1991, BMJ.

[31]  L. Wilhelmsen,et al.  Risk factors for stroke in middle-aged men in Göteborg, Sweden. , 1990, Stroke.

[32]  D. Jacobs,et al.  Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. , 1989, The New England journal of medicine.

[33]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[34]  J. Neaton,et al.  Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). , 1986, JAMA.

[35]  Daniel B Hier,et al.  Race, sex and occlusive cerebrovascular disease: a review. , 1986, Stroke.

[36]  C. E. Becker The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. , 1984, JAMA.

[37]  H. Kato,et al.  Cerebrovascular Diseases in a Fixed Population of 653 Hiroshima and Nagasaki, With Special Reference to Relationship Between Type and Risk Factors , 1984, Stroke.

[38]  A. V. Peterson,et al.  Serum cholesterol, other risk factors, and cardiovascular disease in a Japanese cohort. , 1984, Journal of chronic diseases.

[39]  C. Date,et al.  Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. , 1982, Stroke.

[40]  The coronary primary prevention trial: design and implementation: the Lipid Research Clinics Program. , 1979, Journal of chronic diseases.

[41]  D. Grafnetter,et al.  A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. , 1978, British heart journal.

[42]  W. Holmes The Multiple Risk Factor Intervention Trial (MRFIT) , 1977 .

[43]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[44]  C. Rimington,et al.  Symptomatic porphyria in a case of Felty's syndrome. I. Clinical and routine biochemcial studies. , 1972, Clinical chemistry.